Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Neither saxagliptin or alogliptin cut CV risk, studies suggest

  • Print
  • Comment
  • Save

The new oral hypoglycaemic drugs saxagliptin and alogliptin do not reduce the risk of cardiovascular events in the short term, according to two studies published this week.

An analysis published earlier this year suggested that DPP-4 inhibitors – which effectively lower blood glucose in people with type 2 diabetes - could also lower cardiovascular risk.

But these latest studies - published in the New England Journal of Medicine and set up to study the CV safety of the drugs after the rosiglitazone controversy suggest this might not be the case.

Neither the saxagliptin trial or  the alogliptin trial showed that the drugs decrease patients’ risk of heart attack, stroke, or death, but nor did they increase it in comparison with placebo.

Click here for the full story

 

Have your say

  • Print
  • Comment
  • Save